Global Hormonal Contraceptive Market Size by Product (Combined Oral Contraceptives, Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives, Intrauterine (IUD), Transdermal Patch and Vaginal Rings), By End-use (Hospitals, Clinics, Households) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 – 2027
Industry Trends
Global Hormonal Contraceptive Market was valued at USD 19,759.0 million in 2018 and is estimated to reach USD 28,690.0 million by 2027, growing at a CAGR of 4.2% over the forecast period.
Global Hormonal Contraceptive Market Revenue, 2015 - 2027
There has been a rapid ride of unintended pregnancies and trauma and cost of abortions along with improved technology and heightened awareness among people has propelled the growth of hormonal contraceptives market in the world. Technology to prevent pregnancy with minimum damage and side effects is being conceptualized and developed as we speak. With pro life calls in certain countries and stark opposition, the market does possess its share of threats, but the overall climate globally and increasing governmental intervention and initiatives, Hormonal contraceptives are here to stay.
Pharmaceutical giants like Allegran, Teva and Bayer Inc. have been at the forefront of not only creating safer and more effective hormonal contraceptive methods, but also participating by associating in socially charged initiatives to help increase awareness and use of these contraceptives, thus consolidating their position in the market.
United Nations announced 26 September, as World Contraception Day, to be celebrated every year. According to a report that was published by the World Contraception Day Coalition Committee powered by United Nations, more than 41% of the 208 million pregnancies that occur each year are unplanned, most of which result in abortions. More than 30 million of these recorded unintended pregnancies happen due to failure of contraceptive or erroneous use. The same also has resulted in increasing mortality among women, largely aged between 15- 19 years. Evolving Contraception methods have the potential to avoid unplanned pregnancies and thus abortions and consequent deaths. Developing countries have witnessed this negative surge and a combined figure surpassing 800 million have expressed concern over possible pregnancies they want to avoid. There is augmenting need and scope for the contraceptive market to grow and thrive. Research, policy effort, private involvement and general awareness, that now fueling growth in the hormonal contraceptive market in developed countries, needs acceleration with respect to emerging and developing economies.
Countries around the world are actively participating, with changes in existing policies to accommodate women’s healthcare and safety needs. Hormonal contraception is being adopted increasingly by people. Combined Oral Contraceptives, Oral Contraceptives, Injectable Contraceptives, Implantable Contraceptives, Intrauterine (IUD), Transdermal Patch and Vaginal Rings are the various methods that have seen many structural changes in the last few decades. These methods are further divided on the basis of hormones; progestin only and combined estrogen and progestin and its varying representations applications. There is also a stiff competition between these products with some have more effectual results with lesser side effects, over another. Their country wise landscape also varied.
Oral (Combined) hormonal contraceptive method has been the most opted for in the world, with US taking precedence in its introduction and usage. This method that prevents pregnancy is not without apparent side effects, thus driving the global hormonal contraceptive market. Reports on dangers associated with Oral hormonal contraception, have increased the administration of IUD and vaginal rings. Injective and patch hormonal contraceptives are more prevalent in African countries when compared to North American, Europe, Asia Pacific and Middle Eastern Regions.
Most of the Hormonal Contraceptive Products are available at the prescription of the physician, with the exception, especially emergency contraceptive pills, that have found wide recognition through media and television ads. There is a strong demand for developing hormonal contraception that affords easy availability and is cost effective. This in turn is advancing channelized growth for the hormonal contraceptive market.
Many countries with inherent moral dilemma are still facing issues with contraception. Countries like China and India, need the most attention with contraception with their rapid increase in population. There is also a very ambivalent reaction to hormonal contraception in US, with some states rallying against in amid increasing protests from factions to make contraception and easy availability. There is also parallel development in the male hormonal contraception arena, that is still under progress.
North America hormonal contraceptive market continues to be the largest for hormonal contraceptives in the world, with a rate of 99% success witnessed among the users of oral contraception. US alone takes the largest market share. Middle East and Africa have also shown a steady increase owing to more exposure and better designated attempts to counter problems like infertility, lifestyle disorders, obesity and more aided with the entry of global key players.
The report provides both, qualitative and quantitative research of global hormonal contraceptive market, it also provides penetrative insights into the rational scenario and favored development methods adopted by key contenders. The report also offers extensive research on the key players in the market and detailed insights into the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by major players are also recognized and analyzed in the report. For each company, the report recognizes its headquarters, competitors, product/service type, application and specification, pricing, and gross margin.
Competitive Landscape
Major industry participants in Hormonal Contraceptive market include. Allergan, Bayer Pharmaceuticals that provide Long-acting reversible contraception using intrauterine delivery systems (IUS). Cipla, Merck & Co., Inc, Teva Pharmaceutical Industries Ltd (RAJANI- a generic version of Beyaz), Novartis and Piramal pharma Solutions, provide oral hormonal contraceptives pills. The patch market is confined to Evra, marketed in Canada by Janssen-Ortho and in the United Kingdom and other countries by Janssen-Cilag and Xulane in the United States. New product launches, geographical expansions are some of the major strategies adopted by these players to gain a competitive edge.
By Method:
- Combined oral contraceptives
- Oral contraceptives
- Injectable contraceptives
- Implantable contraceptives
- Intrauterine
- Transdermal patch
- Vaginal rings
By Hormones:
- Androgen
- Estrogen
- Progestogens
- Gonadotropins
- Antiandrogens
- Others
By End User
- Hospitals
- Clinics
- Households
- Others
By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Benelux Union
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Argentina
- Brazil
- Rest of Latin America
1.
Market Scope
1.1.
Market Segmentation
1.2.
Years Considered
1.2.1.
Historic Years: 2013 - 2017
1.2.2.
Base Year: 2018
1.2.3.
Forecast Years: 2019 – 2027
2.
Key Target Audiences
3.
Research Methodology
3.1.
Primary Research
3.1.1.
Research Questionnaire
3.1.2.
Global Percentage Breakdown
3.1.3.
Primary Interviews: Key Opinion
Leaders (KOLs)
3.2.
Secondary Research
3.2.1.
Paid Databases
3.2.2.
Secondary Sources
3.3.
Market Size Estimates
3.3.1.
Top-Down Approach
3.3.2.
Bottom-Up Approach
3.4.
Data Triangulation Methodology
3.5.
Research Assumptions
4.
Recommendations and Insights
from AMI’s Perspective**
5.
Holistic Overview of Hormonal
Contraceptive Market
6.
Market Synopsis: Hormonal Contraceptive Market
7.
Hormonal Contraceptive Market
Analysis: Qualitative Perspective
7.1.
Introduction
7.1.1.
Product Definition
7.1.2.
Industry Development
7.2.
Market Dynamics
7.2.1.
Drivers
7.2.2.
Restraints
7.2.3.
Opportunities
7.3.
Trends in Hormonal Contraceptive
Market
7.4.
Market Determinants Radar Chart
7.5.
Macro-Economic and
Micro-Economic Indicators: Hormonal Contraceptive Market
7.6.
Industry Gross Margin Overview
7.7.
Porter’s Five Force Analysis
8.
Global Hormonal Contraceptive
Market Analysis and Forecasts, 2019 – 2027
8.1.
Overview
8.1.1.
Global Hormonal Contraceptive
Market Revenue (US$ Mn)
8.2.
Global Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
8.2.1.
Combined oral contraceptives
8.2.1.1.
Definition
8.2.1.2.
Market Penetration, 2018
8.2.1.3.
Market Estimation, 2013 – 2018
8.2.1.4.
Market Forecast, 2019 – 2027
8.2.1.5.
Compound Annual Growth Rate
(CAGR)
8.2.1.6.
Regional Bifurcation
8.2.1.6.1.
North America
8.2.1.6.1.1.
Market Estimation, 2013 – 2018
8.2.1.6.1.2.
Market Forecast, 2019 – 2027
8.2.1.6.2.
Europe
8.2.1.6.2.1.
Market Estimation, 2013 – 2018
8.2.1.6.2.2.
Market Forecast, 2019 – 2027
8.2.1.6.3.
Asia Pacific
8.2.1.6.3.1.
Market Estimation, 2013 – 2018
8.2.1.6.3.2.
Market Forecast, 2019 – 2027
8.2.1.6.4.
Middle East and Africa
8.2.1.6.4.1.
Market Estimation, 2013 – 2018
8.2.1.6.4.2.
Market Forecast, 2019 – 2027
8.2.1.6.5.
Latin America
8.2.1.6.5.1.
Market Estimation, 2013 – 2018
8.2.1.6.5.2.
Market Forecast, 2019 – 2027
8.2.2.
Oral contraceptives
8.2.2.1.
Definition
8.2.2.2.
Market Penetration, 2018
8.2.2.3.
Market Estimation, 2013 – 2018
8.2.2.4.
Market Forecast, 2019 – 2027
8.2.2.5.
Compound Annual Growth Rate
(CAGR)
8.2.2.6.
Regional Bifurcation
8.2.2.6.1.
North America
8.2.2.6.1.1.
Market Estimation, 2013 – 2018
8.2.2.6.1.2.
Market Forecast, 2019 – 2027
8.2.2.6.2.
Europe
8.2.2.6.2.1.
Market Estimation, 2013 – 2018
8.2.2.6.2.2.
Market Forecast, 2019 – 2027
8.2.2.6.3.
Asia Pacific
8.2.2.6.3.1.
Market Estimation, 2013 – 2018
8.2.2.6.3.2.
Market Forecast, 2019 – 2027
8.2.2.6.4.
Middle East and Africa
8.2.2.6.4.1.
Market Estimation, 2013 – 2018
8.2.2.6.4.2.
Market Forecast, 2019 – 2027
8.2.2.6.5.
Latin America
8.2.2.6.5.1.
Market Estimation, 2013 – 2018
8.2.2.6.5.2.
Market Forecast, 2019 – 2027
8.2.3.
Injectable contraceptives
8.2.3.1.
Definition
8.2.3.2.
Market Penetration, 2018
8.2.3.3.
Market Estimation, 2013 – 2018
8.2.3.4.
Market Forecast, 2019 – 2027
8.2.3.5.
Compound Annual Growth Rate
(CAGR)
8.2.3.6.
Regional Bifurcation
8.2.3.6.1.
North America
8.2.3.6.1.1.
Market Estimation, 2013 – 2018
8.2.3.6.1.2.
Market Forecast, 2019 – 2027
8.2.3.6.2.
Europe
8.2.3.6.2.1.
Market Estimation, 2013 – 2018
8.2.3.6.2.2.
Market Forecast, 2019 – 2027
8.2.3.6.3.
Asia Pacific
8.2.3.6.3.1.
Market Estimation, 2013 – 2018
8.2.3.6.3.2.
Market Forecast, 2019 – 2027
8.2.3.6.4.
Middle East and Africa
8.2.3.6.4.1.
Market Estimation, 2013 – 2018
8.2.3.6.4.2.
Market Forecast, 2019 – 2027
8.2.3.6.5.
Latin America
8.2.3.6.5.1.
Market Estimation, 2013 – 2018
8.2.3.6.5.2.
Market Forecast, 2019 – 2027
8.2.4.
Implantable contraceptives
8.2.4.1.
Definition
8.2.4.2.
Market Penetration, 2018
8.2.4.3.
Market Estimation, 2013 – 2018
8.2.4.4.
Market Forecast, 2019 – 2027
8.2.4.5.
Compound Annual Growth Rate
(CAGR)
8.2.4.6.
Regional Bifurcation
8.2.4.6.1.
North America
8.2.4.6.1.1.
Market Estimation, 2013 – 2018
8.2.4.6.1.2.
Market Forecast, 2019 – 2027
8.2.4.6.2.
Europe
8.2.4.6.2.1.
Market Estimation, 2013 – 2018
8.2.4.6.2.2.
Market Forecast, 2019 – 2027
8.2.4.6.3.
Asia Pacific
8.2.4.6.3.1.
Market Estimation, 2013 – 2018
8.2.4.6.3.2.
Market Forecast, 2019 – 2027
8.2.4.6.4.
Middle East and Africa
8.2.4.6.4.1.
Market Estimation, 2013 – 2018
8.2.4.6.4.2.
Market Forecast, 2019 – 2027
8.2.4.6.5.
Latin America
8.2.4.6.5.1.
Market Estimation, 2013 – 2018
8.2.4.6.5.2.
Market Forecast, 2019 – 2027
8.2.5.
Intrauterine
8.2.5.1.
Definition
8.2.5.2.
Market Penetration, 2018
8.2.5.3.
Market Estimation, 2013 – 2018
8.2.5.4.
Market Forecast, 2019 – 2027
8.2.5.5.
Compound Annual Growth Rate
(CAGR)
8.2.5.6.
Regional Bifurcation
8.2.5.6.1.
North America
8.2.5.6.1.1.
Market Estimation, 2013 – 2018
8.2.5.6.1.2.
Market Forecast, 2019 – 2027
8.2.5.6.2.
Europe
8.2.5.6.2.1.
Market Estimation, 2013 – 2018
8.2.5.6.2.2.
Market Forecast, 2019 – 2027
8.2.5.6.3.
Asia Pacific
8.2.5.6.3.1.
Market Estimation, 2013 – 2018
8.2.5.6.3.2.
Market Forecast, 2019 – 2027
8.2.5.6.4.
Middle East and Africa
8.2.5.6.4.1.
Market Estimation, 2013 – 2018
8.2.5.6.4.2.
Market Forecast, 2019 – 2027
8.2.5.6.5.
Latin America
8.2.5.6.5.1.
Market Estimation, 2013 – 2018
8.2.5.6.5.2.
Market Forecast, 2019 – 2027
8.2.6.
Transdermal patch
8.2.6.1.
Definition
8.2.6.2.
Market Penetration, 2018
8.2.6.3.
Market Estimation, 2013 – 2018
8.2.6.4.
Market Forecast, 2019 – 2027
8.2.6.5.
Compound Annual Growth Rate
(CAGR)
8.2.6.6.
Regional Bifurcation
8.2.6.6.1.
North America
8.2.6.6.1.1.
Market Estimation, 2013 – 2018
8.2.6.6.1.2.
Market Forecast, 2019 – 2027
8.2.6.6.2.
Europe
8.2.6.6.2.1.
Market Estimation, 2013 – 2018
8.2.6.6.2.2.
Market Forecast, 2019 – 2027
8.2.6.6.3.
Asia Pacific
8.2.6.6.3.1.
Market Estimation, 2013 – 2018
8.2.6.6.3.2.
Market Forecast, 2019 – 2027
8.2.6.6.4.
Middle East and Africa
8.2.6.6.4.1.
Market Estimation, 2013 – 2018
8.2.6.6.4.2.
Market Forecast, 2019 – 2027
8.2.6.6.5.
Latin America
8.2.6.6.5.1.
Market Estimation, 2013 – 2018
8.2.6.6.5.2.
Market Forecast, 2019 – 2027
8.2.7.
Vaginal rings
8.2.7.1.
Definition
8.2.7.2.
Market Penetration, 2018
8.2.7.3.
Market Estimation, 2013 – 2018
8.2.7.4.
Market Forecast, 2019 – 2027
8.2.7.5.
Compound Annual Growth Rate
(CAGR)
8.2.7.6.
Regional Bifurcation
8.2.7.6.1.
North America
8.2.7.6.1.1.
Market Estimation, 2013 – 2018
8.2.7.6.1.2.
Market Forecast, 2019 – 2027
8.2.7.6.2.
Europe
8.2.7.6.2.1.
Market Estimation, 2013 – 2018
8.2.7.6.2.2.
Market Forecast, 2019 – 2027
8.2.7.6.3.
Asia Pacific
8.2.7.6.3.1.
Market Estimation, 2013 – 2018
8.2.7.6.3.2.
Market Forecast, 2019 – 2027
8.2.7.6.4.
Middle East and Africa
8.2.7.6.4.1.
Market Estimation, 2013 – 2018
8.2.7.6.4.2.
Market Forecast, 2019 – 2027
8.2.7.6.5.
Latin America
8.2.7.6.5.1.
Market Estimation, 2013 – 2018
8.2.7.6.5.2.
Market Forecast, 2019 – 2027
8.3.
Key Segment for Channeling
Investments
8.3.1.
By Method
9.
Global Hormonal Contraceptive
Market Analysis and Forecasts, 2019 – 2027
9.1.
Overview
9.2.
Global Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
9.2.1.
Androgen
9.2.1.1.
Definition
9.2.1.2.
Market Penetration, 2018
9.2.1.3.
Market Estimation, 2013 – 2018
9.2.1.4.
Market Forecast, 2019 – 2027
9.2.1.5.
Compound Annual Growth Rate
(CAGR)
9.2.1.6.
Regional Bifurcation
9.2.1.6.1.
North America
9.2.1.6.1.1.
Market Estimation, 2013 – 2018
9.2.1.6.1.2.
Market Forecast, 2019 – 2027
9.2.1.6.2.
Europe
9.2.1.6.2.1.
Market Estimation, 2013 – 2018
9.2.1.6.2.2.
Market Forecast, 2019 – 2027
9.2.1.6.3.
Asia Pacific
9.2.1.6.3.1.
Market Estimation, 2013 – 2018
9.2.1.6.3.2.
Market Forecast, 2019 – 2027
9.2.1.6.4.
Middle East and Africa
9.2.1.6.4.1.
Market Estimation, 2013 – 2018
9.2.1.6.4.2.
Market Forecast, 2019 – 2027
9.2.1.6.5.
Latin America
9.2.1.6.5.1.
Market Estimation, 2013 – 2018
9.2.1.6.5.2.
Market Forecast, 2019 – 2027
9.2.2.
Estrogen
9.2.2.1.
Definition
9.2.2.2.
Market Penetration, 2018
9.2.2.3.
Market Estimation, 2013 – 2018
9.2.2.4.
Market Forecast, 2019 – 2027
9.2.2.5.
Compound Annual Growth Rate
(CAGR)
9.2.2.6.
Regional Bifurcation
9.2.2.6.1.
North America
9.2.2.6.1.1.
Market Estimation, 2013 – 2018
9.2.2.6.1.2.
Market Forecast, 2019 – 2027
9.2.2.6.2.
Europe
9.2.2.6.2.1.
Market Estimation, 2013 – 2018
9.2.2.6.2.2.
Market Forecast, 2019 – 2027
9.2.2.6.3.
Asia Pacific
9.2.2.6.3.1.
Market Estimation, 2013 – 2018
9.2.2.6.3.2.
Market Forecast, 2019 – 2027
9.2.2.6.4.
Middle East and Africa
9.2.2.6.4.1.
Market Estimation, 2013 – 2018
9.2.2.6.4.2.
Market Forecast, 2019 – 2027
9.2.2.6.5.
Latin America
9.2.2.6.5.1.
Market Estimation, 2013 – 2018
9.2.2.6.5.2.
Market Forecast, 2019 – 2027
9.2.3.
Progestogens
9.2.3.1.
Definition
9.2.3.2.
Market Penetration, 2018
9.2.3.3.
Market Estimation, 2013 – 2018
9.2.3.4.
Market Forecast, 2019 – 2027
9.2.3.5.
Compound Annual Growth Rate
(CAGR)
9.2.3.6.
Regional Bifurcation
9.2.3.6.1.
North America
9.2.3.6.1.1.
Market Estimation, 2013 – 2018
9.2.3.6.1.2.
Market Forecast, 2019 – 2027
9.2.3.6.2.
Europe
9.2.3.6.2.1.
Market Estimation, 2013 – 2018
9.2.3.6.2.2.
Market Forecast, 2019 – 2027
9.2.3.6.3.
Asia Pacific
9.2.3.6.3.1.
Market Estimation, 2013 – 2018
9.2.3.6.3.2.
Market Forecast, 2019 – 2027
9.2.3.6.4.
Middle East and Africa
9.2.3.6.4.1.
Market Estimation, 2013 – 2018
9.2.3.6.4.2.
Market Forecast, 2019 – 2027
9.2.3.6.5.
Latin America
9.2.3.6.5.1.
Market Estimation, 2013 – 2018
9.2.3.6.5.2.
Market Forecast, 2019 – 2027
9.2.4.
Gonadotropins
9.2.4.1.
Definition
9.2.4.2.
Market Penetration, 2018
9.2.4.3.
Market Estimation, 2013 – 2018
9.2.4.4.
Market Forecast, 2019 – 2027
9.2.4.5.
Compound Annual Growth Rate
(CAGR)
9.2.4.6.
Regional Bifurcation
9.2.4.6.1.
North America
9.2.4.6.1.1.
Market Estimation, 2013 – 2018
9.2.4.6.1.2.
Market Forecast, 2019 – 2027
9.2.4.6.2.
Europe
9.2.4.6.2.1.
Market Estimation, 2013 – 2018
9.2.4.6.2.2.
Market Forecast, 2019 – 2027
9.2.4.6.3.
Asia Pacific
9.2.4.6.3.1.
Market Estimation, 2013 – 2018
9.2.4.6.3.2.
Market Forecast, 2019 – 2027
9.2.4.6.4.
Middle East and Africa
9.2.4.6.4.1.
Market Estimation, 2013 – 2018
9.2.4.6.4.2.
Market Forecast, 2019 – 2027
9.2.4.6.5.
Latin America
9.2.4.6.5.1.
Market Estimation, 2013 – 2018
9.2.4.6.5.2.
Market Forecast, 2019 – 2027
9.2.5.
Antiandrogens
9.2.5.1.
Definition
9.2.5.2.
Market Penetration, 2018
9.2.5.3.
Market Estimation, 2013 – 2018
9.2.5.4.
Market Forecast, 2019 – 2027
9.2.5.5.
Compound Annual Growth Rate
(CAGR)
9.2.5.6.
Regional Bifurcation
9.2.5.6.1.
North America
9.2.5.6.1.1.
Market Estimation, 2013 – 2018
9.2.5.6.1.2.
Market Forecast, 2019 – 2027
9.2.5.6.2.
Europe
9.2.5.6.2.1.
Market Estimation, 2013 – 2018
9.2.5.6.2.2.
Market Forecast, 2019 – 2027
9.2.5.6.3.
Asia Pacific
9.2.5.6.3.1.
Market Estimation, 2013 – 2018
9.2.5.6.3.2.
Market Forecast, 2019 – 2027
9.2.5.6.4.
Middle East and Africa
9.2.5.6.4.1.
Market Estimation, 2013 – 2018
9.2.5.6.4.2.
Market Forecast, 2019 – 2027
9.2.5.6.5.
Latin America
9.2.5.6.5.1.
Market Estimation, 2013 – 2018
9.2.5.6.5.2.
Market Forecast, 2019 – 2027
9.2.6.
Others
9.2.6.1.
Definition
9.2.6.2.
Market Penetration, 2018
9.2.6.3.
Market Estimation, 2013 – 2018
9.2.6.4.
Market Forecast, 2019 – 2027
9.2.6.5.
Compound Annual Growth Rate
(CAGR)
9.2.6.6.
Regional Bifurcation
9.2.6.6.1.
North America
9.2.6.6.1.1.
Market Estimation, 2013 – 2018
9.2.6.6.1.2.
Market Forecast, 2019 – 2027
9.2.6.6.2.
Europe
9.2.6.6.2.1.
Market Estimation, 2013 – 2018
9.2.6.6.2.2.
Market Forecast, 2019 – 2027
9.2.6.6.3.
Asia Pacific
9.2.6.6.3.1.
Market Estimation, 2013 – 2018
9.2.6.6.3.2.
Market Forecast, 2019 – 2027
9.2.6.6.4.
Middle East and Africa
9.2.6.6.4.1.
Market Estimation, 2013 – 2018
9.2.6.6.4.2.
Market Forecast, 2019 – 2027
9.2.6.6.5.
Latin America
9.2.6.6.5.1.
Market Estimation, 2013 – 2018
9.2.6.6.5.2.
Market Forecast, 2019 – 2027
9.3.
Key Segment for Channeling
Investments
9.3.1.
By Hormones
10. North America Hormonal Contraceptive Market Analysis and
Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North America Hormonal Contraceptive Market Revenue (US$ Mn)
10.2. North America Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Method
10.2.1. Combined oral contraceptives
10.2.2. Oral contraceptives
10.2.3. Injectable contraceptives
10.2.4. Implantable contraceptives
10.2.5. Intrauterine
10.2.6. Transdermal patch
10.2.7. Vaginal rings
10.3. North America Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Hormones
10.3.1. Androgen
10.3.2. Estrogen
10.3.3. Progestogens
10.3.4. Gonadotropins
10.3.5. Antiandrogens
10.3.6. Others
10.4. North America Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Country
10.4.1. U.S
10.4.1.1.
U.S Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
10.4.1.1.1.
Combined oral contraceptives
10.4.1.1.2.
Oral contraceptives
10.4.1.1.3.
Injectable contraceptives
10.4.1.1.4.
Implantable contraceptives
10.4.1.1.5.
Intrauterine
10.4.1.1.6.
Transdermal patch
10.4.1.1.7.
Vaginal rings
10.4.1.2.
U.S Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
10.4.1.2.1.
Androgen
10.4.1.2.2.
Estrogen
10.4.1.2.3.
Progestogens
10.4.1.2.4.
Gonadotropins
10.4.1.2.5.
Antiandrogens
10.4.1.2.6.
Others
10.4.2. Canada
10.4.2.1.
Canada Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
10.4.2.1.1.
Combined oral contraceptives
10.4.2.1.2.
Oral contraceptives
10.4.2.1.3.
Injectable contraceptives
10.4.2.1.4.
Implantable contraceptives
10.4.2.1.5.
Intrauterine
10.4.2.1.6.
Transdermal patch
10.4.2.1.7.
Vaginal rings
10.4.2.2.
Canada Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
10.4.2.2.1.
Androgen
10.4.2.2.2.
Estrogen
10.4.2.2.3.
Progestogens
10.4.2.2.4.
Gonadotropins
10.4.2.2.5.
Antiandrogens
10.4.2.2.6.
Others
10.4.3. Mexico
10.4.3.1.
Mexico Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
10.4.3.1.1.
Combined oral contraceptives
10.4.3.1.2.
Oral contraceptives
10.4.3.1.3.
Injectable contraceptives
10.4.3.1.4.
Implantable contraceptives
10.4.3.1.5.
Intrauterine
10.4.3.1.6.
Transdermal patch
10.4.3.1.7.
Vaginal rings
10.4.3.2.
Mexico Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
10.4.3.2.1.
Androgen
10.4.3.2.2.
Estrogen
10.4.3.2.3.
Progestogens
10.4.3.2.4.
Gonadotropins
10.4.3.2.5.
Antiandrogens
10.4.3.2.6.
Others
10.4.4. Rest of North America
10.4.4.1.
Rest of North America Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
10.4.4.1.1.
Combined oral contraceptives
10.4.4.1.2.
Oral contraceptives
10.4.4.1.3.
Injectable contraceptives
10.4.4.1.4.
Implantable contraceptives
10.4.4.1.5.
Intrauterine
10.4.4.1.6.
Transdermal patch
10.4.4.1.7.
Vaginal rings
10.4.4.2.
Rest of North America Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
10.4.4.2.1.
Androgen
10.4.4.2.2.
Estrogen
10.4.4.2.3.
Progestogens
10.4.4.2.4.
Gonadotropins
10.4.4.2.5.
Antiandrogens
10.4.4.2.6.
Others
10.5. Key Segment for Channeling Investments
10.5.1. By Country
10.5.2. By Method
10.5.3. By Hormones
11. Europe Hormonal Contraceptive Market Analysis and Forecasts,
2019 - 2027
11.1. Overview
11.1.1. Europe Hormonal Contraceptive Market Revenue (US$ Mn)
11.2. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and
Forecasts, By Method
11.2.1. Combined oral contraceptives
11.2.2. Oral contraceptives
11.2.3. Injectable contraceptives
11.2.4. Implantable contraceptives
11.2.5. Intrauterine
11.2.6. Transdermal patch
11.2.7. Vaginal rings
11.3. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and
Forecasts, By Hormones
11.3.1. Androgen
11.3.2. Estrogen
11.3.3. Progestogens
11.3.4. Gonadotropins
11.3.5. Antiandrogens
11.3.6. Others
11.4. Europe Hormonal Contraceptive Market Revenue (US$ Mn) and
Forecasts, By Country
11.4.1. France
11.4.1.1.
France Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
11.4.1.1.1.
Combined oral contraceptives
11.4.1.1.2.
Oral contraceptives
11.4.1.1.3.
Injectable contraceptives
11.4.1.1.4.
Implantable contraceptives
11.4.1.1.5.
Intrauterine
11.4.1.1.6.
Transdermal patch
11.4.1.1.7.
Vaginal rings
11.4.1.2.
France Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.1.2.1.
Androgen
11.4.1.2.2.
Estrogen
11.4.1.2.3.
Progestogens
11.4.1.2.4.
Gonadotropins
11.4.1.2.5.
Antiandrogens
11.4.1.2.6.
Others
11.4.2. The UK
11.4.2.1.
The UK Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
11.4.2.1.1.
Combined oral contraceptives
11.4.2.1.2.
Oral contraceptives
11.4.2.1.3.
Injectable contraceptives
11.4.2.1.4.
Implantable contraceptives
11.4.2.1.5.
Intrauterine
11.4.2.1.6.
Transdermal patch
11.4.2.1.7.
Vaginal rings
11.4.2.2.
The UK Hormonal Contraceptive Market
Revenue (US$ Mn) and Forecasts, By Hormones
11.4.2.2.1.
Androgen
11.4.2.2.2.
Estrogen
11.4.2.2.3.
Progestogens
11.4.2.2.4.
Gonadotropins
11.4.2.2.5.
Antiandrogens
11.4.2.2.6.
Others
11.4.3. Spain
11.4.3.1.
Spain Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
11.4.3.1.1.
Combined oral contraceptives
11.4.3.1.2.
Oral contraceptives
11.4.3.1.3.
Injectable contraceptives
11.4.3.1.4.
Implantable contraceptives
11.4.3.1.5.
Intrauterine
11.4.3.1.6.
Transdermal patch
11.4.3.1.7.
Vaginal rings
11.4.3.2.
Spain Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.3.2.1.
Androgen
11.4.3.2.2.
Estrogen
11.4.3.2.3.
Progestogens
11.4.3.2.4.
Gonadotropins
11.4.3.2.5.
Antiandrogens
11.4.3.2.6.
Others
11.4.4. Germany
11.4.4.1.
Germany Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
11.4.4.1.1.
Combined oral contraceptives
11.4.4.1.2.
Oral contraceptives
11.4.4.1.3.
Injectable contraceptives
11.4.4.1.4.
Implantable contraceptives
11.4.4.1.5.
Intrauterine
11.4.4.1.6.
Transdermal patch
11.4.4.1.7.
Vaginal rings
11.4.4.2.
Germany Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.4.2.1.
Androgen
11.4.4.2.2.
Estrogen
11.4.4.2.3.
Progestogens
11.4.4.2.4.
Gonadotropins
11.4.4.2.5.
Antiandrogens
11.4.4.2.6.
Others
11.4.5. Italy
11.4.5.1.
Italy Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
11.4.5.1.1.
Combined oral contraceptives
11.4.5.1.2.
Oral contraceptives
11.4.5.1.3.
Injectable contraceptives
11.4.5.1.4.
Implantable contraceptives
11.4.5.1.5.
Intrauterine
11.4.5.1.6.
Transdermal patch
11.4.5.1.7.
Vaginal rings
11.4.5.2.
Italy Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.5.2.1.
Androgen
11.4.5.2.2.
Estrogen
11.4.5.2.3.
Progestogens
11.4.5.2.4.
Gonadotropins
11.4.5.2.5.
Antiandrogens
11.4.5.2.6.
Others
11.4.6. Nordic Countries
11.4.6.1.
Nordic Countries Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
11.4.6.1.1.
Combined oral contraceptives
11.4.6.1.2.
Oral contraceptives
11.4.6.1.3.
Injectable contraceptives
11.4.6.1.4.
Implantable contraceptives
11.4.6.1.5.
Intrauterine
11.4.6.1.6.
Transdermal patch
11.4.6.1.7.
Vaginal rings
11.4.6.2.
Nordic Countries Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.6.2.1.
Androgen
11.4.6.2.2.
Estrogen
11.4.6.2.3.
Progestogens
11.4.6.2.4.
Gonadotropins
11.4.6.2.5.
Antiandrogens
11.4.6.2.6.
Others
11.4.6.3.
Nordic Countries Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1.
Denmark
11.4.6.3.2.
Finland
11.4.6.3.3.
Iceland
11.4.6.3.4.
Sweden
11.4.6.3.5.
Norway
11.4.7. Benelux Union
11.4.7.1.
Benelux Union Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
11.4.7.1.1.
Combined oral contraceptives
11.4.7.1.2.
Oral contraceptives
11.4.7.1.3.
Injectable contraceptives
11.4.7.1.4.
Implantable contraceptives
11.4.7.1.5.
Intrauterine
11.4.7.1.6.
Transdermal patch
11.4.7.1.7.
Vaginal rings
11.4.7.2.
Benelux Union Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.7.2.1.
Androgen
11.4.7.2.2.
Estrogen
11.4.7.2.3.
Progestogens
11.4.7.2.4.
Gonadotropins
11.4.7.2.5.
Antiandrogens
11.4.7.2.6.
Others
11.4.7.3.
Benelux Union Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1.
Belgium
11.4.7.3.2.
The Netherlands
11.4.7.3.3.
Luxembourg
11.4.8. Rest of Europe
11.4.8.1.
Rest of Europe Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
11.4.8.1.1.
Combined oral contraceptives
11.4.8.1.2.
Oral contraceptives
11.4.8.1.3.
Injectable contraceptives
11.4.8.1.4.
Implantable contraceptives
11.4.8.1.5.
Intrauterine
11.4.8.1.6.
Transdermal patch
11.4.8.1.7.
Vaginal rings
11.4.8.2.
Rest of Europe Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
11.4.8.2.1.
Androgen
11.4.8.2.2.
Estrogen
11.4.8.2.3.
Progestogens
11.4.8.2.4.
Gonadotropins
11.4.8.2.5.
Antiandrogens
11.4.8.2.6.
Others
11.5. Key Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Method
11.5.3. By Hormones
12. Asia Pacific Hormonal Contraceptive Market Analysis and
Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn)
12.2. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Method
12.2.1. Combined oral contraceptives
12.2.2. Oral contraceptives
12.2.3. Injectable contraceptives
12.2.4. Implantable contraceptives
12.2.5. Intrauterine
12.2.6. Transdermal patch
12.2.7. Vaginal rings
12.3. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Hormones
12.3.1. Androgen
12.3.2. Estrogen
12.3.3. Progestogens
12.3.4. Gonadotropins
12.3.5. Antiandrogens
12.3.6. Others
12.4. Asia Pacific Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Country
12.4.1. China
12.4.1.1.
China Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
12.4.1.1.1.
Combined oral contraceptives
12.4.1.1.2.
Oral contraceptives
12.4.1.1.3.
Injectable contraceptives
12.4.1.1.4.
Implantable contraceptives
12.4.1.1.5.
Intrauterine
12.4.1.1.6.
Transdermal patch
12.4.1.1.7.
Vaginal rings
12.4.1.2.
China Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.1.2.1.
Androgen
12.4.1.2.2.
Estrogen
12.4.1.2.3.
Progestogens
12.4.1.2.4.
Gonadotropins
12.4.1.2.5.
Antiandrogens
12.4.1.2.6.
Others
12.4.2. Japan
12.4.2.1.
Japan Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
12.4.2.1.1.
Combined oral contraceptives
12.4.2.1.2.
Oral contraceptives
12.4.2.1.3.
Injectable contraceptives
12.4.2.1.4.
Implantable contraceptives
12.4.2.1.5.
Intrauterine
12.4.2.1.6.
Transdermal patch
12.4.2.1.7.
Vaginal rings
12.4.2.2.
Japan Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.2.2.1.
Androgen
12.4.2.2.2.
Estrogen
12.4.2.2.3.
Progestogens
12.4.2.2.4.
Gonadotropins
12.4.2.2.5.
Antiandrogens
12.4.2.2.6.
Others
12.4.3. India
12.4.3.1.
India Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
12.4.3.1.1.
Combined oral contraceptives
12.4.3.1.2.
Oral contraceptives
12.4.3.1.3.
Injectable contraceptives
12.4.3.1.4.
Implantable contraceptives
12.4.3.1.5.
Intrauterine
12.4.3.1.6.
Transdermal patch
12.4.3.1.7.
Vaginal rings
12.4.3.2.
India Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.3.2.1.
Androgen
12.4.3.2.2.
Estrogen
12.4.3.2.3.
Progestogens
12.4.3.2.4.
Gonadotropins
12.4.3.2.5.
Antiandrogens
12.4.3.2.6.
Others
12.4.4. New Zealand
12.4.4.1.
New Zealand Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
12.4.4.1.1.
Combined oral contraceptives
12.4.4.1.2.
Oral contraceptives
12.4.4.1.3.
Injectable contraceptives
12.4.4.1.4.
Implantable contraceptives
12.4.4.1.5.
Intrauterine
12.4.4.1.6.
Transdermal patch
12.4.4.1.7.
Vaginal rings
12.4.4.2.
New Zealand Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.4.2.1.
Androgen
12.4.4.2.2.
Estrogen
12.4.4.2.3.
Progestogens
12.4.4.2.4.
Gonadotropins
12.4.4.2.5.
Antiandrogens
12.4.4.2.6.
Others
12.4.5. Australia
12.4.5.1.
Australia Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
12.4.5.1.1.
Combined oral contraceptives
12.4.5.1.2.
Oral contraceptives
12.4.5.1.3.
Injectable contraceptives
12.4.5.1.4.
Implantable contraceptives
12.4.5.1.5.
Intrauterine
12.4.5.1.6.
Transdermal patch
12.4.5.1.7.
Vaginal rings
12.4.5.2.
Australia Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.5.2.1.
Androgen
12.4.5.2.2.
Estrogen
12.4.5.2.3.
Progestogens
12.4.5.2.4.
Gonadotropins
12.4.5.2.5.
Antiandrogens
12.4.5.2.6.
Others
12.4.6. South Korea
12.4.6.1.
South Korea Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
12.4.6.1.1.
Combined oral contraceptives
12.4.6.1.2.
Oral contraceptives
12.4.6.1.3.
Injectable contraceptives
12.4.6.1.4.
Implantable contraceptives
12.4.6.1.5.
Intrauterine
12.4.6.1.6.
Transdermal patch
12.4.6.1.7.
Vaginal rings
12.4.6.2.
South Korea Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.6.2.1.
Androgen
12.4.6.2.2.
Estrogen
12.4.6.2.3.
Progestogens
12.4.6.2.4.
Gonadotropins
12.4.6.2.5.
Antiandrogens
12.4.6.2.6.
Others
12.4.7. Southeast Asia
12.4.7.1.
Southeast Asia Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
12.4.7.1.1.
Combined oral contraceptives
12.4.7.1.2.
Oral contraceptives
12.4.7.1.3.
Injectable contraceptives
12.4.7.1.4.
Implantable contraceptives
12.4.7.1.5.
Intrauterine
12.4.7.1.6.
Transdermal patch
12.4.7.1.7.
Vaginal rings
12.4.7.2.
Southeast Asia Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.7.2.1.
Androgen
12.4.7.2.2.
Estrogen
12.4.7.2.3.
Progestogens
12.4.7.2.4.
Gonadotropins
12.4.7.2.5.
Antiandrogens
12.4.7.2.6.
Others
12.4.7.3.
Southeast Asia Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1.
Indonesia
12.4.7.3.2.
Thailand
12.4.7.3.3.
Malaysia
12.4.7.3.4.
Singapore
12.4.7.3.5.
Rest of Southeast Asia
12.4.8. Rest of Asia Pacific
12.4.8.1.
Rest of Asia Pacific Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
12.4.8.1.1.
Combined oral contraceptives
12.4.8.1.2.
Oral contraceptives
12.4.8.1.3.
Injectable contraceptives
12.4.8.1.4.
Implantable contraceptives
12.4.8.1.5.
Intrauterine
12.4.8.1.6.
Transdermal patch
12.4.8.1.7.
Vaginal rings
12.4.8.2.
Rest of Asia Pacific Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
12.4.8.2.1.
Androgen
12.4.8.2.2.
Estrogen
12.4.8.2.3.
Progestogens
12.4.8.2.4.
Gonadotropins
12.4.8.2.5.
Antiandrogens
12.4.8.2.6.
Others
12.5. Key Segment for Channeling Investments
12.5.1. By Country
12.5.2. By Method
12.5.3. By Hormones
13. Middle East and Africa Hormonal Contraceptive Market Analysis
and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle East and Africa Hormonal Contraceptive Market Revenue
(US$ Mn)
13.2. Middle East and Africa Hormonal Contraceptive Market Revenue
(US$ Mn) and Forecasts, By Method
13.2.1. Combined oral contraceptives
13.2.2. Oral contraceptives
13.2.3. Injectable contraceptives
13.2.4. Implantable contraceptives
13.2.5. Intrauterine
13.2.6. Transdermal patch
13.2.7. Vaginal rings
13.3. Middle East and Africa Hormonal Contraceptive Market Revenue
(US$ Mn) and Forecasts, By Hormones
13.3.1. Androgen
13.3.2. Estrogen
13.3.3. Progestogens
13.3.4. Gonadotropins
13.3.5. Antiandrogens
13.3.6. Others
13.4. Middle East and Africa Hormonal Contraceptive Market Revenue
(US$ Mn) and Forecasts, By Country
13.4.1. Saudi Arabia
13.4.1.1.
Saudi Arabia Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
13.4.1.1.1.
Combined oral contraceptives
13.4.1.1.2.
Oral contraceptives
13.4.1.1.3.
Injectable contraceptives
13.4.1.1.4.
Implantable contraceptives
13.4.1.1.5.
Intrauterine
13.4.1.1.6.
Transdermal patch
13.4.1.1.7.
Vaginal rings
13.4.1.2.
Saudi Arabia Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.1.2.1.
Androgen
13.4.1.2.2.
Estrogen
13.4.1.2.3.
Progestogens
13.4.1.2.4.
Gonadotropins
13.4.1.2.5.
Antiandrogens
13.4.1.2.6.
Others
13.4.2. UAE
13.4.2.1.
UAE Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
13.4.2.1.1.
Combined oral contraceptives
13.4.2.1.2.
Oral contraceptives
13.4.2.1.3.
Injectable contraceptives
13.4.2.1.4.
Implantable contraceptives
13.4.2.1.5.
Intrauterine
13.4.2.1.6.
Transdermal patch
13.4.2.1.7.
Vaginal rings
13.4.2.2.
UAE Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.2.2.1.
Androgen
13.4.2.2.2.
Estrogen
13.4.2.2.3.
Progestogens
13.4.2.2.4.
Gonadotropins
13.4.2.2.5.
Antiandrogens
13.4.2.2.6.
Others
13.4.3. Egypt
13.4.3.1.
Egypt Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
13.4.3.1.1.
Combined oral contraceptives
13.4.3.1.2.
Oral contraceptives
13.4.3.1.3.
Injectable contraceptives
13.4.3.1.4.
Implantable contraceptives
13.4.3.1.5.
Intrauterine
13.4.3.1.6.
Transdermal patch
13.4.3.1.7.
Vaginal rings
13.4.3.2.
Egypt Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.3.2.1.
Androgen
13.4.3.2.2.
Estrogen
13.4.3.2.3.
Progestogens
13.4.3.2.4.
Gonadotropins
13.4.3.2.5.
Antiandrogens
13.4.3.2.6.
Others
13.4.4. Kuwait
13.4.4.1.
Kuwait Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
13.4.4.1.1.
Combined oral contraceptives
13.4.4.1.2.
Oral contraceptives
13.4.4.1.3.
Injectable contraceptives
13.4.4.1.4.
Implantable contraceptives
13.4.4.1.5.
Intrauterine
13.4.4.1.6.
Transdermal patch
13.4.4.1.7.
Vaginal rings
13.4.4.2.
Kuwait Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.4.2.1.
Androgen
13.4.4.2.2.
Estrogen
13.4.4.2.3.
Progestogens
13.4.4.2.4.
Gonadotropins
13.4.4.2.5.
Antiandrogens
13.4.4.2.6.
Others
13.4.5. South Africa
13.4.5.1.
South Africa Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
13.4.5.1.1.
Combined oral contraceptives
13.4.5.1.2.
Oral contraceptives
13.4.5.1.3.
Injectable contraceptives
13.4.5.1.4.
Implantable contraceptives
13.4.5.1.5.
Intrauterine
13.4.5.1.6.
Transdermal patch
13.4.5.1.7.
Vaginal rings
13.4.5.2.
South Africa Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.5.2.1.
Androgen
13.4.5.2.2.
Estrogen
13.4.5.2.3.
Progestogens
13.4.5.2.4.
Gonadotropins
13.4.5.2.5.
Antiandrogens
13.4.5.2.6.
Others
13.4.6. Rest of Middle East & Africa
13.4.6.1.
Rest of Middle East & Africa
Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
13.4.6.1.1.
Combined oral contraceptives
13.4.6.1.2.
Oral contraceptives
13.4.6.1.3.
Injectable contraceptives
13.4.6.1.4.
Implantable contraceptives
13.4.6.1.5.
Intrauterine
13.4.6.1.6.
Transdermal patch
13.4.6.1.7.
Vaginal rings
13.4.6.2.
Rest of Middle East & Africa
Hormonal Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
13.4.6.2.1.
Androgen
13.4.6.2.2.
Estrogen
13.4.6.2.3.
Progestogens
13.4.6.2.4.
Gonadotropins
13.4.6.2.5.
Antiandrogens
13.4.6.2.6.
Others
13.5. Key Segment for Channeling Investments
13.5.1. By Country
13.5.2. By Method
13.5.3. By Hormones
14. Latin America Hormonal Contraceptive Market Analysis and
Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin America Hormonal Contraceptive Market Revenue (US$ Mn)
14.2. Latin America Hormonal Contraceptive Market Revenue (US$ Mn) and
Forecasts, By Method
14.2.1. Combined oral contraceptives
14.2.2. Oral contraceptives
14.2.3. Injectable contraceptives
14.2.4. Implantable contraceptives
14.2.5. Intrauterine
14.2.6. Transdermal patch
14.2.7. Vaginal rings
14.3. Latin America Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Hormones
14.3.1. Androgen
14.3.2. Estrogen
14.3.3. Progestogens
14.3.4. Gonadotropins
14.3.5. Antiandrogens
14.3.6. Others
14.4. Latin America Hormonal Contraceptive Market Revenue (US$ Mn)
and Forecasts, By Country
14.4.1. Brazil
14.4.1.1.
Brazil Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
14.4.1.1.1.
Combined oral contraceptives
14.4.1.1.2.
Oral contraceptives
14.4.1.1.3.
Injectable contraceptives
14.4.1.1.4.
Implantable contraceptives
14.4.1.1.5.
Intrauterine
14.4.1.1.6.
Transdermal patch
14.4.1.1.7.
Vaginal rings
14.4.1.2.
Brazil Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
14.4.1.2.1.
Androgen
14.4.1.2.2.
Estrogen
14.4.1.2.3.
Progestogens
14.4.1.2.4.
Gonadotropins
14.4.1.2.5.
Antiandrogens
14.4.1.2.6.
Others
14.4.2. Argentina
14.4.2.1.
Argentina Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Method
14.4.2.1.1.
Combined oral contraceptives
14.4.2.1.2.
Oral contraceptives
14.4.2.1.3.
Injectable contraceptives
14.4.2.1.4.
Implantable contraceptives
14.4.2.1.5.
Intrauterine
14.4.2.1.6.
Transdermal patch
14.4.2.1.7.
Vaginal rings
14.4.2.2.
Argentina Hormonal Contraceptive
Market Revenue (US$ Mn) and Forecasts, By Hormones
14.4.2.2.1.
Androgen
14.4.2.2.2.
Estrogen
14.4.2.2.3.
Progestogens
14.4.2.2.4.
Gonadotropins
14.4.2.2.5.
Antiandrogens
14.4.2.2.6.
Others
14.4.3. Rest of Latin America
14.4.3.1.
Rest of Latin America Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Method
14.4.3.1.1.
Combined oral contraceptives
14.4.3.1.2.
Oral contraceptives
14.4.3.1.3.
Injectable contraceptives
14.4.3.1.4.
Implantable contraceptives
14.4.3.1.5.
Intrauterine
14.4.3.1.6.
Transdermal patch
14.4.3.1.7.
Vaginal rings
14.4.3.2.
Rest of Latin America Hormonal
Contraceptive Market Revenue (US$ Mn) and Forecasts, By Hormones
14.4.3.2.1.
Androgen
14.4.3.2.2.
Estrogen
14.4.3.2.3.
Progestogens
14.4.3.2.4.
Gonadotropins
14.4.3.2.5.
Antiandrogens
14.4.3.2.6.
Others
14.5. Key Segment for Channeling Investments
14.5.1. By Country
14.5.2. By Method
14.5.3. By Hormones
15. Competitive Benchmarking
15.1. Brand Benchmarking
15.2. Market Share Analysis, 2018
15.3. Global Presence and Growth Strategies
15.3.1. Mergers and Acquisitions
15.3.2. Product Launches
15.3.3. Investments Trends
15.3.4. R&D Initiatives
16. Player Profiles
16.1. Allergan
16.1.1. Company Details
16.1.2. Company Overview
16.1.3. Product Offerings
16.1.4. Key Developments
16.1.5. Financial Analysis
16.1.6. SWOT Analysis
16.1.7. Business Strategies
16.2. Bayer Pharmaceuticals
16.2.1. Company Details
16.2.2. Company Overview
16.2.3. Product Offerings
16.2.4. Key Developments
16.2.5. Financial Analysis
16.2.6. SWOT Analysis
16.2.7. Business Strategies
16.3. Cipla
16.3.1. Company Details
16.3.2. Company Overview
16.3.3. Product Offerings
16.3.4. Key Developments
16.3.5. Financial Analysis
16.3.6. SWOT Analysis
16.3.7. Business Strategies
16.4. Merck and Co., Inc.
16.4.1. Company Details
16.4.2. Company Overview
16.4.3. Product Offerings
16.4.4. Key Developments
16.4.5. Financial Analysis
16.4.6. SWOT Analysis
16.4.7. Business Strategies
16.5. Novartis
16.5.1. Company Details
16.5.2. Company Overview
16.5.3. Product Offerings
16.5.4. Key Developments
16.5.5. Financial Analysis
16.5.6. SWOT Analysis
16.5.7. Business Strategies
16.6. Piramal pharma Solutions
16.6.1. Company Details
16.6.2. Company Overview
16.6.3. Product Offerings
16.6.4. Key Developments
16.6.5. Financial Analysis
16.6.6. SWOT Analysis
16.6.7. Business Strategies
16.7. Teva Pharmaceutical Industries Ltd
16.7.1. Company Details
16.7.2. Company Overview
16.7.3. Product Offerings
16.7.4. Key Developments
16.7.5. Financial Analysis
16.7.6. SWOT Analysis
16.7.7. Business Strategies
16.8. Other Market Participants
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.